...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Endocrine Research >The effect of low dose nylestriol-levonorgestrel replacement therapy on bone mineral density in women with postmenopausal osteoporosis.
【24h】

The effect of low dose nylestriol-levonorgestrel replacement therapy on bone mineral density in women with postmenopausal osteoporosis.

机译：低剂量nylestriol-levonorgestrel替代疗法对绝经后骨质疏松症妇女骨矿物质密度的影响。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

OBJECTIVE: Recently our studies have shown that nylestriol in combination with levonorgestrel prevented bone loss, decreased bone turnover rate and increased the maximal loading of bone without obvious side effects in retinoic acid (RA) induced osteoporotic rats. In addition to the animal experiments, we evaluate the effect of Compound Nylestriol Tablet (CNT) on bone mineral density (BMD) in women with postmenopausal osteoporosis. Compound Nylestriol Tablet, which contains 0.5 mg of nylestriol (cyclopentylethinyl estriol) and 0.15 mg of levonorgestrel per tablet, was authorized as a new anti-osteoporotic agent for clinical trial in postmenopausal osteoporosis. METHODS: One year's clinical observation was performed in 191 eligible patients who were randomly divided into two groups (A and B). In group A, 119 patients were treated for one year with CNT (one tablet per week) and in group B, 72 patients with placebo. Bone mineral density of lumbar antero-posterior spine (L1-L4), lateral spine, total hip andtotal forearm positions including radius+ulna at the ultra distal areas, mid areas, and one-third areas, were measured before and after treatment. Biochemical parameters and effects of CNT on uterus, and breast were observed. RESULTS: We found that patients treated with CNT had a significant decrease of bone loss in total forearm, including radius+ulna at the ultra distal, mid, and 1/3 areas compared with control subjects (all P < 0.05). An improved BMD tendency could be seen at the lumbar spine. There were no differences in the observed biochemical variables. No side-effects on uterus, or mammary glands observed. None of the patients had uterine bleeding or vertebral fractures during one year's CNT treatment. CONCLUSION: These data suggested that CNT is effective, safe and convenient in treating postmenopausal osteoporosis.
机译：目的：近期我们的研究表明，在视黄酸（RA）引起的骨质疏松大鼠中，nylestriol与左炔诺孕酮联合可预防骨质流失，降低骨转换率并增加最大骨负荷，而没有明显的副作用。除动物实验外，我们还评估了化合物Nylestriol片（CNT）对绝经后骨质疏松症女性骨矿物质密度（BMD）的影响。化合物Nylestriol片剂每片含0.5 mg的nylestriol（环戊炔基雌三醇）和0.15 mg的左炔诺孕酮，被批准作为一种新型的抗骨质疏松剂，可用于绝经后骨质疏松症的临床试验。方法：对191名符合条件的患者进行了为期一年的临床观察，他们被随机分为两组（A和B）。在A组中，有119例患者接受了CNT治疗（一年一粒，每周一次），而B组中有72例接受了安慰剂治疗。在治疗前后，分别测量腰椎前后骨（L1-L4），外侧脊椎，整个前臂和整个前臂位置（包括radius骨+尺骨）的骨矿物质密度。观察了CNT的生化参数以及对子宫和乳房的影响。结果：我们发现，与对照组相比，接受CNT治疗的患者的前臂总骨量明显减少，包括radius骨远端+中侧和1/3区域的ul骨+尺骨（所有P <0.05）。腰椎骨密度可以改善。观察到的生化变量没有差异。没有观察到对子宫或乳腺的副作用。在一年的CNT治疗期间，没有患者发生子宫出血或椎骨骨折。结论：这些数据表明碳纳米管治疗绝经后骨质疏松症安全，有效，方便。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号